{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:21:09Z","timestamp":1778934069884,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clml.2024.10.009","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T07:16:30Z","timestamp":1729062990000},"page":"304-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["SOHO State of the Art Updates and Next Questions | The Current State of CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Jonathan M.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-9672","authenticated-orcid":false,"given":"Tycel J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.10.009_bib0001","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1182\/blood-2023-190022","article-title":"Updated trends in incidence and survival of mantle cell lymphoma from 2000 to 2020","volume":"142","author":"Arora","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.10.009_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol.2019.03.01","article-title":"Mantle cell lymphoma pathology update in the 2016 WHO classification","volume":"3","author":"Veloza","year":"2019","journal-title":"Ann Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2024.10.009_bib0003","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0002-9440(10)65399-0","article-title":"Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization","volume":"154","author":"Li","year":"1999","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.clml.2024.10.009_bib0004","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.10.009_bib0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.18697","article-title":"How I manage mantle cell lymphoma: indolent versus aggressive disease","volume":"201","author":"Wilson","year":"2023","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2024.10.009_bib0006","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/leu.2012.72","article-title":"Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease","volume":"26","author":"Royo","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2024.10.009_bib0007","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo\u2013purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"10044","key":"10.1016\/j.clml.2024.10.009_bib0008","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clml.2024.10.009_bib0009","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.10.009_bib0010","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.10.009_bib0011","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2024.10.009_bib0012","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"9873","key":"10.1016\/j.clml.2024.10.009_bib0013","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clml.2024.10.009_bib0014","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.10.009_bib0015","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.3747\/co.27.7053","article-title":"First-line therapy, autologous stem-cell transplantation, and post-transplantation maintenance in the management of newly diagnosed mantle cell lymphoma","volume":"27","author":"Bhella","year":"2020","journal-title":"Curr Oncol"},{"issue":"13","key":"10.1016\/j.clml.2024.10.009_bib0016","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"10121","key":"10.1016\/j.clml.2024.10.009_bib0017","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.clml.2024.10.009_bib0018","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"10441","key":"10.1016\/j.clml.2024.10.009_bib0019","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"Dreyling","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.clml.2024.10.009_bib0020","doi-asserted-by":"crossref","first-page":"8262787","DOI":"10.1155\/2022\/8262787","article-title":"Outcomes among patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States: a real-world electronic medical records study","volume":"2022","author":"Hess","year":"2022","journal-title":"Adv Hematol"},{"issue":"6","key":"10.1016\/j.clml.2024.10.009_bib0021","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.10.009_bib0022","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2024.10.009_bib0024","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2024.10.009_bib0025","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a Phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2024.10.009_bib0026","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-Hodgkin lymphomas: extended follow-up of a Phase I\/II study","volume":"42","author":"Budde","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.10.009_bib0027","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2022-157777","article-title":"Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma","volume":"140","author":"Phillips","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.10.009_bib0028","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.clml.2024.10.009_bib0029","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.clml.2024.10.009_bib0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.10.009_bib0031","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood-2023-179474","article-title":"TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.10.009_bib0032","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"The Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.10.009_bib0033","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.clml.2024.10.009_bib0034","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.10.009_bib0035","doi-asserted-by":"crossref","first-page":"TPS7578","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7578","article-title":"ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.10.009_bib0036","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.10.009_bib0037","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2023-179269","article-title":"Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R\/R) mantle cell lymphoma (MCL): a CIBMTR subgroup analysis of high-risk characteristics","volume":"142","author":"Kambhampati","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.10.009_bib0038","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood-2021-147563","article-title":"Brexucabtagene autoleucel for relapsed\/refractory mantle cell lymphoma: real world experience from the US lymphoma CAR T consortium","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.10.009_bib0039","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1200\/JCO.2024.42.16_suppl.7016","volume":"42","author":"Palomba","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.10.009_bib0040","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.10.009_bib0041","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood-2021-146032","article-title":"Worsening financial toxicity among patients receiving chimeric antigen receptor T-cell (CAR-T) therapy: a mixed methods longitudinal study","volume":"138","author":"Cusatis","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2024.10.009_bib0042","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"10306","key":"10.1016\/j.clml.2024.10.009_bib0043","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clml.2024.10.009_bib0044","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.10.009_bib0045","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: initial results from a phase Ib\/II study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.10.009_bib0046","series-title":"Glofitamab Monotherapy in Patients With Heavily Pretreated Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma (MCL): Updated Analysis from a Phase I\/II Study","author":"Phillips","year":"2024"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.10.009_bib0047","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2023-173946","article-title":"GLOBRYTE: a phase III, open-label, multicenter, randomized trial evaluating glofitamab monotherapy in patients with relapsed or refractory mantle cell lymphoma","volume":"142","author":"Phillips","year":"2023","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2024.10.009_bib0048","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.10.009_bib0049","unstructured":"NCT. A phase II study evaluating glofitamab in combination with venetoclax plus zanubrutinib or venetoclax alone in subjects with untreated or relapsed\/refractory high-risk mantle-cell lymphoma (GLOASIS). Accessed September 12, 2024; Available from: https:\/\/clinicaltrials.gov\/study\/NCT06558604?cond=Mantle%20Cell%20Lymphoma&intr=glofitamab&rank=3."},{"key":"10.1016\/j.clml.2024.10.009_bib0050","unstructured":"NCT. A Phase 2 trial of glofitamab and pirtobrutinib in mantle cell lymphoma patients with prior BTK inhibitor exposure. (GOlDiLOX) Accessed September 12, 2024 Available from: https:\/\/clinicaltrials.gov\/study\/NCT05833763?cond=Mantle%20Cell%20Lymphoma&intr=glofitamab&rank=1."},{"key":"10.1016\/j.clml.2024.10.009_bib0051","unstructured":"NCT. Glofitamab with pirtobrutinib for relapsed or refractory mantle cell lymphoma. Accessed September 12, 2024; Available from: https:\/\/clinicaltrials.gov\/study\/NCT06252675?cond=Mantle%20Cell%20Lymphoma&intr=glofitamab&rank=4."},{"key":"10.1016\/j.clml.2024.10.009_bib0052","unstructured":"NCT. A study of glofitamab and lenalidomide in people with mantle cell lymphoma. Accessed September 12, 2024 Available from: https:\/\/clinicaltrials.gov\/study\/NCT06192888?cond=Mantle%20Cell%20Lymphoma&intr=glofitamab&rank=2."},{"key":"10.1016\/j.clml.2024.10.009_bib0053","unstructured":"NCT. Glofitamab plus ibrutinib with obinutuzumab for the treatment of patients with mantle cell lymphoma. Accessed September 12, 2024 Available from: https:\/\/clinicaltrials.gov\/study\/NCT06357676?cond=Mantle%20Cell%20Lymphoma&intr=glofitamab&rank=6."},{"key":"10.1016\/j.clml.2024.10.009_bib0054","unstructured":"NCT. Acalabrutinib, obinutuzumab, and glofitamab for the treatment of relapsed or refractory mantle cell lymphoma. Accessed September 12, 2024; Available from: https:\/\/clinicaltrials.gov\/study\/NCT06054776?cond=Mantle%20Cell%20Lymphoma&intr=glofitamab&rank=5."},{"issue":"13_Supplement","key":"10.1016\/j.clml.2024.10.009_bib0055","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1158\/1538-7445.AM2017-3636","article-title":"Abstract 3636: potent antitumor activity of duvortuxizumab, a CD19 x CD3 DART\u00ae molecule, in lymphoma models","volume":"77","author":"Izhak","year":"2017","journal-title":"Cancer Res"},{"issue":"8_Supplement","key":"10.1016\/j.clml.2024.10.009_bib0056","doi-asserted-by":"crossref","first-page":"LB218","DOI":"10.1158\/1538-7445.AM2023-LB218","article-title":"Abstract LB218: Developing a bispecific anti-ROR1 antibody drug conjugate for hematological and solid tumor treatment","volume":"83","author":"Zhao","year":"2023","journal-title":"Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.10.009_bib0057","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2023-172980","article-title":"Innate cell engager (ICE\u00ae) AFM13 combined with preactivated and expanded (P+E) cord blood (CB)-derived natural killer (NK) cells for patients with refractory CD30-positive lymphomas: final results","volume":"142","author":"Nieto","year":"2023","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:17:22Z","timestamp":1762600642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024023802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2152265024023802"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | The Current State of CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}